-

Innovaderm Research, a Dual Focus CRO, Appoints Jeff Smith as New CEO

MONTREAL--(BUSINESS WIRE)--Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients.

Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles.

Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation. Innovaderm is excited to add therapeutic expertise in rheumatology in addition to our world class dermatology research services, further expanding our capabilities and dedication to advancing medical knowledge and new therapies as a dual-focused CRO. Mr. Smith’s proven track record in organizational expansion and achieving meaningful and impactful results will be invaluable in driving these efforts forward.

“I am truly honored to join Innovaderm as CEO and collaborate with such a dedicated and talented team. Together, we are poised to work together with our sponsors to drive innovation in clinical research, making meaningful advancements in dermatology and rheumatology that will directly benefit patients and improve their quality of life.” Jeff Smith

Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the CRO’s continuity and stability. His ongoing leadership will continue to guide Innovaderm’s mission to advance clinical research and improve patient outcomes. “I am confident Jeff Smith’s leadership will drive Innovaderm to new heights,” said Dr. Robert Bissonnette.

For more information about our dermatology and rheumatology resources please visit: https://innovaderm.com/

Innovaderm Research Inc.

Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.

Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

Innovaderm Research Inc.



Contacts

For more information:
Valerie Coveney
Communications Specialist
Innovaderm Research Inc.
vcoveney@innovaderm.com

More News From Innovaderm Research Inc.

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

MONTREAL--(BUSINESS WIRE)--Indero, the niche CRO formerly known as Innovaderm, is celebrating 25 years of advancing clinical research. From its roots as a dermatology site in Montreal, Indero has grown into a global organization with capabilities in more than 30 countries across 4 continents and has earned a reputation for delivering expert, efficient trials in dermatology and, more recently, rheumatology. Indero was founded as Innovaderm in 2000, starting as a clinical site and now a global CR...

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

MONTREAL--(BUSINESS WIRE)--Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields. Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculosk...
Back to Newsroom